Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that its CD30 antibody‑drug conjugate (ADC) Adcetris (generic name: brentuximab vedotin for injection) has been officially approved by China’s National Medical Products Administration (NMPA) for use in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30‑positive peripheral T‑cell lymphomas (PTCL), including angioimmunoblastic T‑cell lymphoma (AITL) and PTCL‑not otherwise specified (PTCL‑NOS). Adcetris becomes China’s first and currently only targeted therapy approved for the first‑line treatment of CD30‑positive PTCL.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New first‑line indication |
| Product | Adcetris (brentuximab vedotin for injection) – CD30‑directed ADC |
| Regimen | Adcetris + CHP (cyclophosphamide, doxorubicin, prednisone) |
| Indication | Adults with previously untreated sALCL or other CD30‑positive PTCL, including AITL and PTCL‑NOS |
| Approval Date | 23 Oct 2026 (announcement) |
| Distinction | First and currently only targeted therapy approved in China for first‑line treatment of CD30‑positive PTCL |
| Pivotal Trials | Global Phase III ECHELON‑2; China bridging study C25024 |
Drug Profile & Mechanism of Action
- Molecule: Brentuximab vedotin, a CD30‑directed antibody‑drug conjugate (ADC).
- Mechanism: Binds CD30 expressed on lymphoma cells and delivers a cytotoxic payload, selectively killing CD30‑positive malignant cells while sparing normal tissue.
- Regimen Rationale: Combined with CHP (cyclophosphamide, doxorubicin, prednisone) – replacing the vincristine (O) in standard CHOP – the combination unites targeted ADC activity with anthracycline‑based chemotherapy in the frontline setting.
- Established China Portfolio: Previously approved in China for multiple CD30‑positive lymphoma indications, including relapsed or refractory sALCL, relapsed or refractory classical Hodgkin lymphoma, and primary cutaneous anaplastic large cell lymphoma or mycosis fungoides after prior systemic therapy – the new approval extends the franchise into first‑line use.
Clinical Evidence – ECHELON-2 and China Bridging Study C25024
| Endpoint / Measure | Adcetris + CHP | Comparator / Context | Benefit |
|---|---|---|---|
| Complete Response (CR) Rate | 68% | vs CHOP | Increased CR rate |
| Risk of Disease Progression | Reduced by 30% | vs CHOP | 30% risk reduction |
| Risk of Death | Reduced by 28% | vs CHOP | 28% risk reduction |
| 5‑Year OS Rate (5‑Year Follow‑Up) | 70.1% | – | Durable long‑term survival |
The global Phase III ECHELON‑2 study compared brentuximab vedotin + CHP against CHOP in previously untreated CD30‑positive PTCL: the combination increased the complete response (CR) rate to 68% and reduced the risk of disease progression by 30% and the risk of death by 28%, with 5‑year follow‑up showing a 5‑year OS rate of 70.1% in the combination group – evidence of durable, long‑term benefit.
The China bridging study C25024 enrolled 52 patients with previously untreated CD30‑positive PTCL: 96.2% achieved tumor shrinkage or complete disappearance, 75.0% achieved complete response, and no new safety risks were observed, confirming consistency with the global ECHELON‑2 population and supporting NMPA approval in Chinese patients.
Market Impact & Outlook
- First‑in‑Class in China: As China’s first and currently only targeted therapy for first‑line CD30‑positive PTCL, Adcetris establishes a new standard of care in a disease space where CHOP chemotherapy has been the backbone for decades.
- Broad PTCL Coverage: The indication spans sALCL, AITL, and PTCL‑NOS, addressing the heterogeneous CD30‑positive PTCL spectrum rather than a single subtype – expanding the eligible frontline population.
- Durable Survival Evidence: A 70.1% 5‑year OS rate and statistically significant PFS/OS risk reductions give clinicians long‑term data uncommon in T‑cell lymphoma, where outcomes have historically been poor.
- Local Validation: The C25024 bridging study (52 Chinese patients, 96.2% tumor response, 75.0% CR, no new safety signals) grounds global efficacy in the Chinese population, supporting clinical adoption.
- Franchise Deepening: First‑line PTCL adds to Adcetris’ established China footprint in relapsed/refractory sALCL, classical Hodgkin lymphoma, and cutaneous T‑cell lymphomas, consolidating Takeda’s hematology‑oncology leadership in CD30‑positive lymphomas.
- Next Steps: Commercial launch and reimbursement engagement in China; additional indications or combination expansions were not disclosed beyond this announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Adcetris’ NMPA‑approved first‑line CD30‑positive PTCL indication, clinical benefits observed in ECHELON‑2 and study C25024, and commercial potential in China. Actual results may differ materially due to risks including reimbursement and pricing decisions, real‑world clinical experience, competitive therapies, manufacturing and supply considerations, and further regulatory actions.-Fineline Info & Tech
